Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Novartis Suspected of Drafting Letter of Consent for “Sign” Trial
January 30, 2014
- Sosei Transfers NorLevo MA Rights to ASKA
January 30, 2014
- Mochida Eyes 10 Billion Yen Generic Biz, Valsartan Combination Drug to Debut in 2014: Pres.
January 29, 2014
- Shionogi Influenza Campaign Causes Stir among Healthcare Professionals
January 29, 2014
- Lurasidone Receives CHMP Positive Opinion: DSP, Takeda
January 29, 2014
- Kenko.com Sues Government over Restriction of Online OTC Drug Sales
January 28, 2014
- Asano Named as New Asahi Kasei President
January 28, 2014
- Zydus to Withdraw from Japan, Discontinuing Shipments by March-End Due to Policy Change of Parent Company
January 28, 2014
- Ajinomoto to Downsize In-House Drug Discovery Research amid Slack Pharma Biz
January 27, 2014
- BioWa Out-Licenses Kyowa Hakko Kirin’s Technologies and Serves as Its “In-Licensing Window”; “Naked” Mabs to Remain Dominant until 2002
January 27, 2014
- Sanwa Kagaku, Dong-A ST of South Korea Sign License Deal for Nesp Biosimilar in Japan
January 27, 2014
- Novartis Used Interim Report of “Sign” Trial in Tasigna Promotion, Set to Probe Its Involvement in Protocol Drafting
January 24, 2014
- Antidepressant Brintellix Launched in US: Takeda, Lundbeck
January 24, 2014
- Novartis Adds LABA/LAMA Combination Ultibro to Lineup of Breezhaler Products for COPD Using the Same Inhaler
January 24, 2014
- Novartis Pharma Involvement Suspected in Drafting of Sign Trial Protocol
January 23, 2014
- Azilva Remains No.1 in December “Mind Share” Ranking in GP, HP Markets
January 22, 2014
- Japan’s 1st Sublingual Immunotherapy Wins Approval: Torii
January 21, 2014
- Sales Reps Vied over Questionnaire Transfers in Tasigna Trial, Boss OK’ed Incentive Program: Novartis
January 21, 2014
- NBI Receives Approval for Giotrif, Sets to Enter Oncology Field
January 21, 2014
- Nissan Chemical Sues Nichi-Iko, Two Other Companies over Livalo Patent
January 21, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…